降脂灵胶囊联合非诺贝特治疗高脂血症的疗效及对血清MMP-9、MFG-E8、Klotho水平的影响

目的探讨降脂灵胶囊联合非诺贝特治疗高脂血症的疗效,以及治疗对颈动脉粥样硬化斑块和血清基质金属蛋白酶-9(MMP-9)、乳脂肪球表皮生长因子8(MFG-E8)、Klotho水平的影响。方法选取重庆市第五人民医院2019年4月至2020年7月收治的高脂血症患者92例作为研究对象,按照随机数字表法将患者分为研究组和对照组,每组46例。对照组给予非诺贝特治疗,研究组在对照组基础上联合降脂灵胶囊治疗。对比2组的临床疗效、血脂水平、颈总动脉粥样硬化斑块横切面的最大面积、外周动脉内膜中层厚度(IMT)、血清MMP-9、MFG-E8、Klotho水平及不良反应发生情况。结果研究组总有效率为95.65%,高于对照组的78.26%(P<0.05)。2组治疗后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、MMP-9水平及斑块面积、IMT均低于治疗前,高密度脂蛋白胆固醇(HDL-C)、MFG-E8、Klotho水平均高于治疗前(P<0.05);研究组治疗后TC、TG、LDL-C、MMP-9水平及斑块面积、IMT均低于对照组,HDL-C、MFG-E8、Klotho水平均高于对照组(P<0.05)。2组患者不良反应比较,差异无统计学意义(P>0.05)。结论降脂灵胶囊与非诺贝特联合治疗高脂血症患者疗效明显,可改善血脂水平,缩小颈动脉粥样硬化斑块面积以及IMT,降低血清MMP-9水平,提升血清MFG-E8、Klotho水平,且不良反应少。

Efficacy of Jiangzhiling capsule combined with fenofibrate in the treatment of hyperlipidemia and its effect on serum levels of MMP-9,MFG-E8 and Klotho

Objective To investigate the efficacy of Jiangzhiling capsule combined with fenofibrate in the treatment of hyperlipidemia and the effects of the treatment on carotid atherosclerotic plaque and the serum levels of matrix metalloproteinase-9(MMP-9),milk fat globule epidermal growth factor 8(MFG-E8)and Klotho.Methods Ninety-two patients with hyperlipidemia treated in Chongqing Fifth People′s Hospital from April 2019 to July 2020 were selected as the research subjects.According to the random number table method,they were divided into the study group and the control group,with 46 cases in each group.The control group was treated with fenofibrate,and the study group was treated with Jiangzhiling capsule on the basis of the control group.The clinical efficacy,blood lipid level,maximum area of carotid atherosclerotic plaque in cross section,peripheral artery intima media thickness(IMT),serum MMP-9,MFG-E8,Klotho levels and adverse reactions were compared between the two groups.Results The total effective rate of the study group was 95.65%,which was significantly higher than 78.26%of the control group(P<0.05).After treatment,the levels of total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),MMP-9,plaque area and IMT were lower than those before treatment,and the levels of high-density lipoprotein cholesterol(HDL-C),MFG-E8 and Klotho were higher than those before treatment(P<0.05).After treatment,the levels of TC,TG,LDL-C,MMP-9,plaque area and IMT in the study group were lower than those in the control group,and the levels of HDL-C,MFG-E8 and Klotho in the study group were higher than those in the control group(P<0.05).There was no statistical signifcance in the difference of adverse reactions between the 2 groups(P>0.05).Conclusion The combined treatment of Jiangzhiling capsules and fenofibrate is effective in treating patients with hyperlipidemia,and it can improve blood lipid levels,reduce carotid atherosclerotic plaque area and IMT,reduce serum MMP-9 level,and increase serum MFG-E8 and Klotho levels,with less adverse reactions.